Park E, Jang J, Byun J, Kim J, Lee S, Kim H
Abdom Radiol (NY). 2024; 49(8):2737-2745.
PMID: 38802630
DOI: 10.1007/s00261-024-04299-4.
Henry L, Li J, Arciero C, von Holzen U, Schwarz R, Jatoi I
Ann Surg Open. 2023; 4(1):e236.
PMID: 37600883
PMC: 10431358.
DOI: 10.1097/AS9.0000000000000236.
Mucileanu A, Chira R, Mircea P
Med Pharm Rep. 2022; 94(4):402-410.
PMID: 36105495
PMC: 9389876.
DOI: 10.15386/mpr-2116.
Chu Q, Hsieh M, Gibbs J, Wu X
J Gastrointest Oncol. 2022; 12(6):2579-2590.
PMID: 35070389
PMC: 8748054.
DOI: 10.21037/jgo-20-584.
Palzer J, Eckstein L, Slabu I, Reisen O, Neumann U, Roeth A
Nanomaterials (Basel). 2021; 11(11).
PMID: 34835777
PMC: 8622891.
DOI: 10.3390/nano11113013.
Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic ductal adenocarcinoma.
Ahmed A, Kohler S, Klotz R, Giese N, Lasitschka F, Hackert T
Oncoimmunology. 2021; 10(1):1962135.
PMID: 34408923
PMC: 8366538.
DOI: 10.1080/2162402X.2021.1962135.
Same Chance of Accessing Resection? Impact of Socioeconomic Status on Resection Rates Among Patients with Pancreatic Adenocarcinoma-A Systematic Review.
Thobie A, Mulliri A, Bouvier V, Launoy G, Alves A, Dejardin O
Health Equity. 2021; 5(1):143-150.
PMID: 33778318
PMC: 7990568.
DOI: 10.1089/heq.2019.0099.
The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data.
Bengtsson A, Andersson R, Ansari D
Sci Rep. 2020; 10(1):16425.
PMID: 33009477
PMC: 7532215.
DOI: 10.1038/s41598-020-73525-y.
Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study.
Wang H, Liu J, Xia G, Lei S, Huang X, Huang X
Sci Rep. 2020; 10(1):7048.
PMID: 32341400
PMC: 7184604.
DOI: 10.1038/s41598-020-64068-3.
Development, Validation and Comparison of Artificial Neural Network Models and Logistic Regression Models Predicting Survival of Unresectable Pancreatic Cancer.
Tong Z, Liu Y, Ma H, Zhang J, Lin B, Bao X
Front Bioeng Biotechnol. 2020; 8:196.
PMID: 32232040
PMC: 7082923.
DOI: 10.3389/fbioe.2020.00196.
Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model.
Latenstein A, van Roessel S, van der Geest L, Bonsing B, Dejong C, Groot Koerkamp B
Ann Surg Oncol. 2020; 27(7):2516-2524.
PMID: 32052299
PMC: 7311496.
DOI: 10.1245/s10434-020-08235-w.
Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment.
You M, Lee S, Choi Y, Shin B, Paik W, Ryu J
BMC Cancer. 2019; 19(1):952.
PMID: 31615457
PMC: 6794802.
DOI: 10.1186/s12885-019-6193-0.
Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club.
Winter K, Talar-Wojnarowska R, Dabrowski A, Degowska M, Durlik M, Gasiorowska A
Prz Gastroenterol. 2019; 14(1):1-18.
PMID: 30944673
PMC: 6444110.
DOI: 10.5114/pg.2019.83422.
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.
Blomstrand H, Scheibling U, Bratthall C, Green H, Elander N
BMC Cancer. 2019; 19(1):40.
PMID: 30621618
PMC: 6325739.
DOI: 10.1186/s12885-018-5244-2.
Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
Chen H, He R, Shi X, Zhou M, Zhao C, Zhang H
BMC Cancer. 2018; 18(1):1034.
PMID: 30352573
PMC: 6199735.
DOI: 10.1186/s12885-018-4948-7.
Proposal of a modified American Joint Committee on Cancer staging scheme for resectable pancreatic ductal adenocarcinoma with a lymph node ratio-based N classification: A retrospective cohort study.
Li H, Chen Y, Yuan S
Medicine (Baltimore). 2018; 97(34):e12094.
PMID: 30142869
PMC: 6112900.
DOI: 10.1097/MD.0000000000012094.
Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study.
Kardosh A, Lichtensztajn D, Gubens M, Kunz P, Fisher G, Clarke C
Pancreas. 2018; 47(8):958-966.
PMID: 30074526
PMC: 6095724.
DOI: 10.1097/MPA.0000000000001133.
Factors leading to pancreatic resection in patients with pancreatic cancer: a national perspective.
Pointer Jr D, Al-Qurayshi Z, Hamner J, Slakey D, Kandil E
Gland Surg. 2018; 7(2):207-215.
PMID: 29770314
PMC: 5938269.
DOI: 10.21037/gs.2017.12.04.
Epidurals in Pancreatic Resection Outcomes (E-PRO) study: protocol for a randomised controlled trial.
Pak L, Haroutounian S, Hawkins W, Worley L, Kurtz M, Frey K
BMJ Open. 2018; 8(1):e018787.
PMID: 29374667
PMC: 5829652.
DOI: 10.1136/bmjopen-2017-018787.
The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
Tesfaye A, Kamgar M, Azmi A, Philip P
Expert Rev Anticancer Ther. 2017; 18(2):131-148.
PMID: 29254387
PMC: 6121777.
DOI: 10.1080/14737140.2018.1417844.